Meeting
2021 Gastrointestinal Cancers Symposium
Cost-effectiveness of cetuximab + FOLFIRI versus bevacizumab + FOLFIRI in the first-line treatment of RAS wild-type metastatic colorectal cancer in China.
Authors
Ilse Van Oostrum
Ingress Health, Rotterdam, Netherlands
Ilse Van Oostrum , Yannan Hu , Zijiao Yuan , Michael Schlichting , Libo Tao , Chris P. Pescott
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Colorectal Cancer
Track
Colorectal Cancer
Sub Track
Other
Citation
J Clin Oncol 39, 2021 (suppl 3; abstr 133)
DOI
10.1200/JCO.2021.39.3_suppl.133
Abstract #
133
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
Cost-effectiveness of FOLFIRI + cetuximab vs FOLFIRI + bevacizumab in the first-line (1L) treatment of RAS wild-type (wt) metastatic colorectal cancer (mCRC) in Germany: Data from the FIRE-3 (AIO KRK-0306) study.
First Author: Sebastian Stintzing
Poster
2022 ASCO Annual Meeting
Analysis of plasma angiogenesis factors on the efficacy of first-line (1L) chemotherapy (chemo) combined with biologics in RAS wild-type metastatic colorectal cancer (mCRC): Results from GI-SCREEN CRC Ukit study.
First Author: Satoshi Yuki
Poster
2020 Gastrointestinal Cancers Symposium
Variation in genetic polymorphisms and gene expression of HLA-E to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first-line FOLFIRI/cetuximab: Data from the phase III FIRE-3 trial.
First Author: Madiha Naseem
Poster
2018 ASCO Annual Meeting
Genetic variations in the β2M/HLA-E immunomodulatory complex to predict outcomes in metastatic colorectal cancer (mCRC) patients (pts) treated with first line FOLFIRI/Cetuximab: Data from the phase III FIRE-3 trial.
First Author: Madiha Naseem